Sangamo price target raised to $27 from $22 at JMP Securities JMP Securities increased its price target on Sangamo after meeting with the company's clinical and scientific team. The firm increased its estimate of the likelihood of the company's HIV program succeeding to 60% from 50%. JMP Securities thinks the company is clicking on all cylinders, and reiterates an Outperform rating on the shares.
News For SGMO From The Last 14 Days
Check below for free stories on SGMO the last two weeks.
Sangamo plans to submit IND application for hemophilia B in 2Q15 Sangamo BioSciences (SGMO) plans to submit an Investigational New Drug application for the treatment of hemophilia B in Q2 2015. This program, partnered with Shire (SHPG), is the first therapeutic application of Sangamo's zinc finger nuclease-mediated In Vivo Protein Replacement Platform. Sangamo is developing the IVPRP as a generally applicable strategy to provide a one-time, permanent genetic cure for monogenic diseases that are currently managed by protein replacement therapy, which involves costly repeat infusions over the lifetime of the patient.